Myriad Genetics
MYGN
284 hedge funds and large institutions have $4.01B invested in Myriad Genetics in 2014 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 103 increasing their positions, 107 reducing their positions, and 37 closing their positions.
7% more capital invested
Capital invested by funds: $3.74B → $4.01B (+$272M)
1% more funds holding
Funds holding: 281 → 284 (+3)
8% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 37
4% less repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 107
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
60% less call options, than puts
Call options by funds: $54.6M | Put options by funds: $137M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$78.1M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$54.8M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$49.5M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$28M |
| 5 |
D.E. Shaw & Co
New York
|
+$26.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$70.8M |
| 2 |
MCM
Munder Capital Management
Birmingham,
Michigan
|
-$69.3M |
| 3 |
LCG
Luxor Capital Group
New York
|
-$62.1M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$46M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$44.5M |
MYGN Hedge Fund Activity: Q2 2014 in Review
284 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2014, worth a combined $4.01B — up 7.3% from $3.74B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new MYGN positions and 37 closed out — a net gain of 3 holders — while 103 added to existing stakes and 107 trimmed.
The largest buyer was Capital World Investors, adding an estimated $78.1M. The largest seller was BlackRock Advisors, cutting an estimated $70.8M.
- 284 institutional investors held Myriad Genetics (MYGN) as of Q2 2014, up from 281 in Q1 2014.
- Funds reported $4.01B of Myriad Genetics stock for Q2 2014, up 7.3% quarter-over-quarter.
- 40 funds opened new Myriad Genetics positions in Q2 2014 and 37 closed out, a net change of +3 holders.
- The largest Myriad Genetics buyer in Q2 2014 was Capital World Investors, an estimated $78.1M added.
- The largest Myriad Genetics seller in Q2 2014 was BlackRock Advisors, an estimated $70.8M sold.
Based on aggregated 13F filings for Q2 2014.